Best Ovarian Cancer Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

Ovarian cancer surgery is performed by a gynaecologic oncologist — a surgeon trained specifically in gynaecological cancers, distinct from a general gynaecologist. This distinction is the single most important credential to verify. Around the gynaecologic oncologist, the team needs a medical oncologist experienced with carboplatin + paclitaxel chemotherapy and PARP inhibitors, a pathologist with experience in ovarian cancer subtyping, a genetic counsellor for BRCA testing results, an interventional radiologist for draining abdominal fluid, and (for younger patients) access to fertility preservation services.

An ovarian cancer tumour board reviews scans, blood tumour markers, biopsy results, and intra-operative findings together — and assigns a stage using the international staging system (FIGO): stage I (limited to the ovaries), stage II (spread within the pelvis), stage III (spread within the abdomen), or stage IV (distant spread). The board then issues a written treatment plan covering whether surgery comes first (primary debulking) or chemotherapy comes first (interval debulking), the role of HIPEC if applicable, the chemotherapy regimen, and the preventive PARP inhibitor strategy.

Cytoreductive (debulking) surgery for ovarian cancer is the gynaecological cancer operation with the strongest volume-outcome relationship. The surgeon's ability to leave no visible cancer behind — called complete cytoreduction — is the strongest modifiable factor in long-term survival. Ask: "How many ovarian cancer debulking surgeries did your team perform last year? What proportion achieved complete cytoreduction? What is your post-operative complication rate?" Specific numbers indicate transparency.

Ovarian cancer staging needs contrast-enhanced CT of the abdomen and pelvis, sometimes pelvic ultrasound, and tracking of a blood tumour marker called CA-125 that responds to treatment and helps detect recurrence. Tissue diagnosis is established through image-guided biopsy or sometimes laparoscopy. Crucially, BRCA1, BRCA2, and broader gene-panel testing is now recommended for every ovarian cancer patient — not only those with a family history — because identifying inherited mutations directly determines treatment (PARP inhibitor candidacy) and has implications for family members.

Ovarian cancer chemotherapy is the well-established combination of carboplatin and paclitaxel, typically given as six cycles every three weeks. Higher-risk cases may also receive bevacizumab, an additional infused drug that blocks blood supply to tumours. After chemotherapy, many patients continue on a PARP inhibitor — olaparib, niraparib, or rucaparib — as preventive maintenance treatment for up to two years, and sometimes longer for BRCA-mutated cases. This entire pathway requires regular oncologist review and side-effect management.

Ovarian cancer care occasionally calls on procedures that need specialised infrastructure — most notably HIPEC (heated chemotherapy washed through the abdomen during surgery), which has evidence for stage III patients undergoing interval debulking. Other procedures like extensive bowel resection, diaphragmatic stripping, or splenectomy may also be needed in advanced cases and require an experienced gynaecologic oncology team supported by intensive care. NABH-accredited partners signal audited surgical and procedural safety.

Ovarian cancer treatment is one of the longer cancer pathways — surgery, six months of chemotherapy, and often two or more years of PARP inhibitor maintenance. A hospital that isn't empanelled for your insurance or ArogyaSri at the specific centre where your procedure happens can derail planning at the worst moment. PARP inhibitor coverage in particular has scheme-specific rules.

Ovarian cancer is a chronic disease for many patients. Recurrence is common, and when it happens, treatment continues with second-line and sometimes third-line regimens. Surveillance after initial treatment continues for at least five years with periodic scans, CA-125 tracking, and clinical examinations — every three months in the first two years, then less frequently. You will see your team often. A network of centres close to home — same panel, same protocols, shared records — makes continuity sustainable.

Hospital infrastructure for ovarian cancer is tiered at CION. Surveillance scans, CA-125 monitoring, day-care chemotherapy, PARP inhibitor refills and reviews, and follow-up consultations happen at the centre nearest your home. Cytoreductive surgery, interval debulking, HIPEC, and complex gynaecologic oncology procedures run through NABH-accredited partner hospitals with verified gynaecologic oncology expertise. The same oncology team that consults at one centre stays with you across the network.

CT and MRI imaging — including the contrast-enhanced protocols needed for ovarian cancer staging and recurrence surveillance — are available across six CION centres in Hyderabad. CA-125 tumour marker testing runs through integrated lab pathways with rapid turnaround. Imaging is reviewed by treating oncologists alongside the CION pathology team, with workflow designed to keep treatment on schedule.

CION arranges BRCA1, BRCA2, and broader gene-panel testing through integrated lab pathways for every ovarian cancer patient, in line with international guidelines. Where an inherited mutation is identified, genetic counselling is provided, treatment is optimised for PARP inhibitor maintenance, and at-risk family members are offered testing through a coordinated pathway. This is not optional in 2026 — it is the standard of care.

All 11 CION centres in Hyderabad have day-care infusion bays. Carboplatin + paclitaxel chemotherapy, bevacizumab, and PARP inhibitor maintenance (olaparib, niraparib, rucaparib) are administered close to home — typically six cycles of chemotherapy followed by long-course PARP inhibitor maintenance for eligible patients. Oncology-trained nursing, hypersensitivity-reaction protocols for taxanes, and on-site oncologist supervision are standard at every centre. Long-course PARP inhibitor patients receive regular reviews for side-effect management at their nearest CION centre.

Where an ovarian cancer case requires cytoreductive surgery with HIPEC (heated chemotherapy washed through the abdomen during the operation), extensive interval debulking after initial chemotherapy, or complex gynaecologic oncology surgery involving bowel resection, diaphragmatic stripping, or splenectomy, CION coordinates the procedure through NABH-accredited partner hospitals with established gynaecologic oncology programs and intensive-care capacity. NABH accreditation ensures audited compliance with patient-safety, infection-control, and clinical-governance protocols.

Ovarian cancer is a chronic disease for many patients. Recurrence surveillance with three-monthly CA-125 and clinical examinations for the first two years, scans at defined intervals, planning for recurrence treatment when it occurs, management of treatment-related menopause and bone-health monitoring, lymphoedema management when needed, palliative care integration, and psychological support are all coordinated within the CION network. These are not afterthoughts — they decide whether your overall care is sustainable over many years.

Every ovarian cancer case at CION is reviewed by the multidisciplinary tumour board before the treatment plan is finalised. The board debates the FIGO stage, primary vs interval debulking strategy, HIPEC candidacy, the chemotherapy regimen, gene-testing-led PARP inhibitor decisions, and surveillance planning. The board produces a written summary that becomes part of your records — and yours to keep. You can take it to any second opinion, anywhere.